In EGFR-mutant NSCLC, the APPLE trial demonstrated the feasibility of serial monitoring of ctDNA to inform treatment decisions, identifying 17% of patients with molecular progression prior to RECIST progression [18]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.